PolyPid Ltd., an Israeli biotechnology company, announced today positive preliminary results of a first-in-man clinical trial with BonyPid. In the study, BonyPid demonstrated a clear, positive signal of effect in bone recovery processes, on bones with contaminated open fractures.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments